Myh9-KO Mouse
一般名
Myh9-KO
製品ID
S-KO-16209
背景情報
C57BL/6JCya
系統ID
KOCMP-17886-Myh9-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Myh9-KO Mouse（カタログ番号S-KO-16209）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Myh9-KO
系統ID
KOCMP-17886-Myh9-B6J-VA
遺伝子名
製品ID
S-KO-16209
遺伝子別名
Fltn, Myhn1, Myhn-1, TU72.6, NMHCIIA, NMMHC-A, NMMHC-IIA
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 15
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000016771
NCBIトランスクリプトID
NM_022410
ターゲット領域
Exon 3
有効領域の大きさ
~0.2 kb
遺伝子研究の概要
MYH9, encoding the heavy chain of non-muscle myosin IIA, is a cytoplasmic myosin involved in generating intracellular chemomechanical force and actin cytoskeleton translocation. Its functions are regulated by phosphorylation of light and heavy chains and protein-protein interactions. It plays a role in various biological processes, especially during embryonic development, and is associated with pathways related to cell motility and tissue homeostasis [1].
MYH9-related diseases are caused by its mutations, following an autosomal-dominant pattern. These diseases include a group of rare genetic entities characterized by macrothrombocytopenia, leukocyte inclusions, and risks of renal failure, hearing loss, and cataracts [2]. In hepatocellular carcinoma, silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation, inhibiting tumor stemness [3]. In gastric cancer, nuclear MYH9 promotes CTNNB1 transcription, leading to anoikis resistance and metastasis [4]. In rheumatoid arthritis, MYH9 promotes synoviocyte migration and invasion [5]. MYH9-related platelet disorders are due to MYH9 gene mutations causing premature platelet release, macrothrombocytopenia, and cytoplasmic inclusion bodies in leukocytes [6]. In serous ovarian cancer, MYH9 combines with MYH10 to promote carcinogenesis, progression, and cisplatin resistance [7]. Also, OVGP1 promotes hypertension by interacting with MYH9, inducing vascular remodeling [8].
In conclusion, MYH9 is crucial for intracellular force-generation and cytoskeleton-related processes. Model-based research, especially through gene-knockout studies in relevant animal models, has revealed its diverse roles in multiple disease areas, including blood disorders, cancers, and cardiovascular diseases. Understanding MYH9's functions provides insights into disease mechanisms and potential therapeutic targets.
References:
1. Pecci, Alessandro, Ma, Xuefei, Savoia, Anna, Adelstein, Robert S. 2018. MYH9: Structure, functions and role of non-muscle myosin IIA in human disease. In Gene, 664, 152-167. doi:10.1016/j.gene.2018.04.048. https://pubmed.ncbi.nlm.nih.gov/29679756/
2. Furlano, Mónica, Arlandis, Rosa, Venegas, María Del Prado, Ars, Elisabet, Torra, Roser. 2018. MYH9 Associated nephropathy. In Nefrologia, 39, 133-140. doi:10.1016/j.nefro.2018.08.008. https://pubmed.ncbi.nlm.nih.gov/30471777/
3. Lin, Xian, Li, Ai-Min, Li, Yong-Hao, Liu, Zhen, Fang, Wei-Yi. 2020. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. In Signal transduction and targeted therapy, 5, 13. doi:10.1038/s41392-020-0111-4. https://pubmed.ncbi.nlm.nih.gov/32296025/
4. Ye, Gengtai, Yang, Qingbin, Lei, Xuetao, Yu, Jiang, Li, Guoxin. 2020. Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. In Theranostics, 10, 7545-7560. doi:10.7150/thno.46001. https://pubmed.ncbi.nlm.nih.gov/32685004/
5. Lee, Saseong, Choi, Eunbyeol, Chae, Sehyun, Hwang, Daehee, Kim, Wan-Uk. 2023. Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling. In Annals of the rheumatic diseases, 82, 1035-1048. doi:10.1136/ard-2022-223625. https://pubmed.ncbi.nlm.nih.gov/37188496/
6. Althaus, Karina, Greinacher, Andreas. 2009. MYH9-related platelet disorders. In Seminars in thrombosis and hemostasis, 35, 189-203. doi:10.1055/s-0029-1220327. https://pubmed.ncbi.nlm.nih.gov/19408192/
7. Liu, Longyang, Chen, Chunlin, Liu, Ping, Zeng, Zhaoyang, Fang, Weiyi. 2023. MYH10 Combines with MYH9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous Ovarian Cancer Carcinogenesis, Progression, and Cisplatin Resistance. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2203423. doi:10.1002/advs.202203423. https://pubmed.ncbi.nlm.nih.gov/36929633/
8. Bai, Congxia, Su, Ming, Zhang, Yaohua, Li, Hao, Chen, Jingzhou. 2022. Oviductal Glycoprotein 1 Promotes Hypertension by Inducing Vascular Remodeling Through an Interaction With MYH9. In Circulation, 146, 1367-1382. doi:10.1161/CIRCULATIONAHA.121.057178. https://pubmed.ncbi.nlm.nih.gov/36172862/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。